Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.

HY, Meltzer; L, Arvanitis; D, Bauer; W, Rein

doi:10.1176/appi.ajp.161.6.975

Public

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.

Shared by NobleBlocks on Jun 1, 2004 • 12:00 AM UTC

Authors:

Meltzer HY

Arvanitis L

Bauer D

Abstract

Objective Four studies using identical protocols evaluated the safety and efficacy of four novel, evidence-based targets for antipsychotic agents: a neurokinin (NK(3)) antagonist (SR142801), a serotonin 2A/2C (5-HT(2A/2C)) antagonist (SR46349B), a central cannabinoid (CB(1)) antagonist (SR141716), a...

Discussions